argenx SE (NASDAQ: ARGX) Stock Competitors & Peer Comparison
See ARGX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ARGX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ARGX | $919.21 | -1.79% | 57.2B | 33.14 | $27.73 | N/A |
| VRTX | $504.73 | -0.40% | 128.1B | 26.52 | $19.03 | N/A |
| REGN | $735.20 | +0.05% | 75.7B | 16.11 | $45.63 | +0.50% |
| MRNA | $190.01 | +0.57% | 75.4B | -23.31 | -$8.15 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| RVMDW | $11.41 | -1.64% | 45.2B | -1.31 | -$8.82 | N/A |
| RVMD | $206.64 | +0.36% | 43.9B | -23.43 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $358.07 | -0.20% | 38.3B | 63.04 | $5.68 | N/A |
| ALNY | $219.72 | -4.96% | 29.4B | 39.59 | $5.55 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
ARGX vs VRTX Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, VRTX has a market cap of 128.1B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while VRTX trades at $504.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas VRTX's P/E ratio is 26.52. In terms of profitability, ARGX's ROE is +0.24%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, ARGX is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
ARGX vs REGN Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, REGN has a market cap of 75.7B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while REGN trades at $735.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas REGN's P/E ratio is 16.11. In terms of profitability, ARGX's ROE is +0.24%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ARGX is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check REGN's competition here
Moderna, Inc. (NASDAQ: MRNA)
ARGX vs MRNA Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, MRNA has a market cap of 75.4B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while MRNA trades at $190.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas MRNA's P/E ratio is -23.31. In terms of profitability, ARGX's ROE is +0.24%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, ARGX is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check MRNA's competition here
Verona Pharma plc (NASDAQ: VRNA)
ARGX vs VRNA Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ARGX's ROE is +0.24%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, ARGX is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check VRNA's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
ARGX vs RVMDW Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, RVMDW has a market cap of 45.2B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while RVMDW trades at $11.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas RVMDW's P/E ratio is -1.31. In terms of profitability, ARGX's ROE is +0.24%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, ARGX is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
ARGX vs RVMD Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, RVMD has a market cap of 43.9B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while RVMD trades at $206.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas RVMD's P/E ratio is -23.43. In terms of profitability, ARGX's ROE is +0.24%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, ARGX is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
ARGX vs SGEN Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ARGX's ROE is +0.24%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ARGX is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
ARGX vs ONC Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, ONC has a market cap of 38.3B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while ONC trades at $358.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas ONC's P/E ratio is 63.04. In terms of profitability, ARGX's ROE is +0.24%, compared to ONC's ROE of +0.14%. Regarding short-term risk, ARGX is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
ARGX vs ALNY Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, ALNY has a market cap of 29.4B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while ALNY trades at $219.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas ALNY's P/E ratio is 39.59. In terms of profitability, ARGX's ROE is +0.24%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, ARGX is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
ARGX vs ROIV Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, ROIV has a market cap of 25.8B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while ROIV trades at $35.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas ROIV's P/E ratio is -33.98. In terms of profitability, ARGX's ROE is +0.24%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, ARGX is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ROIV's competition here
BioNTech SE (NASDAQ: BNTX)
ARGX vs BNTX Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, BNTX has a market cap of 24.3B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while BNTX trades at $96.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas BNTX's P/E ratio is -12.57. In terms of profitability, ARGX's ROE is +0.24%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, ARGX is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check BNTX's competition here
Insmed Incorporated (NASDAQ: INSM)
ARGX vs INSM Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, INSM has a market cap of 24.1B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while INSM trades at $111.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas INSM's P/E ratio is -27.04. In terms of profitability, ARGX's ROE is +0.24%, compared to INSM's ROE of -1.11%. Regarding short-term risk, ARGX is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check INSM's competition here
Incyte Corporation (NASDAQ: INCY)
ARGX vs INCY Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, INCY has a market cap of 23.4B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while INCY trades at $115.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas INCY's P/E ratio is 15.50. In terms of profitability, ARGX's ROE is +0.24%, compared to INCY's ROE of +0.30%. Regarding short-term risk, ARGX is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check INCY's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
ARGX vs UTHR Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, UTHR has a market cap of 23B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while UTHR trades at $541.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas UTHR's P/E ratio is 19.38. In terms of profitability, ARGX's ROE is +0.24%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, ARGX is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check UTHR's competition here
Genmab A/S (NASDAQ: GMAB)
ARGX vs GMAB Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, GMAB has a market cap of 21.3B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while GMAB trades at $34.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas GMAB's P/E ratio is 26.19. In terms of profitability, ARGX's ROE is +0.24%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, ARGX is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check GMAB's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
ARGX vs BGNE Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ARGX's ROE is +0.24%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, ARGX is less volatile compared to BGNE. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
ARGX vs DNA-WT Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ARGX's ROE is +0.24%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, ARGX is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check DNA-WT's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
ARGX vs JAZZ Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, JAZZ has a market cap of 14.8B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while JAZZ trades at $235.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas JAZZ's P/E ratio is 8.79. In terms of profitability, ARGX's ROE is +0.24%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, ARGX is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check JAZZ's competition here
Exelixis, Inc. (NASDAQ: EXEL)
ARGX vs EXEL Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, EXEL has a market cap of 14.7B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while EXEL trades at $58.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas EXEL's P/E ratio is 16.68. In terms of profitability, ARGX's ROE is +0.24%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, ARGX is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check EXEL's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
ARGX vs NBIX Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, NBIX has a market cap of 14.4B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while NBIX trades at $143.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas NBIX's P/E ratio is 20.69. In terms of profitability, ARGX's ROE is +0.24%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, ARGX is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check NBIX's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
ARGX vs ASND Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, ASND has a market cap of 14.2B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while ASND trades at $227.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas ASND's P/E ratio is -94.16. In terms of profitability, ARGX's ROE is +0.24%, compared to ASND's ROE of +1.90%. Regarding short-term risk, ARGX is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check ASND's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
ARGX vs SMMT Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, SMMT has a market cap of 13.4B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while SMMT trades at $16.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas SMMT's P/E ratio is -14.96. In terms of profitability, ARGX's ROE is +0.24%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, ARGX is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check SMMT's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
ARGX vs BBIO Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, BBIO has a market cap of 13.2B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while BBIO trades at $67.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas BBIO's P/E ratio is -17.98. In terms of profitability, ARGX's ROE is +0.24%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, ARGX is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check BBIO's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
ARGX vs HALO Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, HALO has a market cap of 12.7B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while HALO trades at $109.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas HALO's P/E ratio is 19.95. In terms of profitability, ARGX's ROE is +0.24%, compared to HALO's ROE of +1.81%. Regarding short-term risk, ARGX is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check HALO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
ARGX vs KRTX Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ARGX's ROE is +0.24%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ARGX is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check KRTX's competition here
10x Genomics, Inc. (NASDAQ: TXG)
ARGX vs TXG Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, TXG has a market cap of 11.9B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while TXG trades at $93.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas TXG's P/E ratio is -158.47. In terms of profitability, ARGX's ROE is +0.24%, compared to TXG's ROE of -0.09%. Regarding short-term risk, ARGX is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check TXG's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
ARGX vs TWST Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, TWST has a market cap of 11.7B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while TWST trades at $188.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas TWST's P/E ratio is -84.99. In terms of profitability, ARGX's ROE is +0.24%, compared to TWST's ROE of -0.30%. Regarding short-term risk, ARGX is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check TWST's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
ARGX vs MDGL Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, MDGL has a market cap of 11.5B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while MDGL trades at $499.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas MDGL's P/E ratio is -39.02. In terms of profitability, ARGX's ROE is +0.24%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, ARGX is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check MDGL's competition here
Bio-Techne Corporation (NASDAQ: TECH)
ARGX vs TECH Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while TECH trades at $72.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas TECH's P/E ratio is 37.32. In terms of profitability, ARGX's ROE is +0.24%, compared to TECH's ROE of +0.09%. Regarding short-term risk, ARGX is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
ARGX vs RNAM Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ARGX's ROE is +0.24%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ARGX is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check RNAM's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
ARGX vs BMRN Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, BMRN has a market cap of 11.1B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while BMRN trades at $57.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas BMRN's P/E ratio is 27.49. In terms of profitability, ARGX's ROE is +0.24%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, ARGX is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check BMRN's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
ARGX vs IBRX Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, IBRX has a market cap of 10.8B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while IBRX trades at $10.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas IBRX's P/E ratio is -10.60. In terms of profitability, ARGX's ROE is +0.24%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, ARGX is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check IBRX's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
ARGX vs RXDX Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ARGX's ROE is +0.24%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ARGX is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check RXDX's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
ARGX vs KRYS Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, KRYS has a market cap of 9.5B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while KRYS trades at $322.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas KRYS's P/E ratio is 40.39. In terms of profitability, ARGX's ROE is +0.24%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ARGX is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check KRYS's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
ARGX vs AXSM Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, AXSM has a market cap of 9.2B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while AXSM trades at $179.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas AXSM's P/E ratio is -46.80. In terms of profitability, ARGX's ROE is +0.24%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, ARGX is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check AXSM's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
ARGX vs NUVL Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ARGX's ROE is +0.24%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ARGX is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check NUVL's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
ARGX vs ARWR Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, ARWR has a market cap of 9B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while ARWR trades at $64.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas ARWR's P/E ratio is -28.53. In terms of profitability, ARGX's ROE is +0.24%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, ARGX is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ARWR's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
ARGX vs PTGX Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, PTGX has a market cap of 9B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while PTGX trades at $140.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas PTGX's P/E ratio is 135.98. In terms of profitability, ARGX's ROE is +0.24%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, ARGX is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check PTGX's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
ARGX vs CRNX Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas CRNX's P/E ratio is -16.86. In terms of profitability, ARGX's ROE is +0.24%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ARGX is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check CRNX's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
ARGX vs KYMR Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, KYMR has a market cap of 8.8B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while KYMR trades at $107.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas KYMR's P/E ratio is -33.56. In terms of profitability, ARGX's ROE is +0.24%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, ARGX is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check KYMR's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
ARGX vs IMGN Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ARGX's ROE is +0.24%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ARGX is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check IMGN's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
ARGX vs BPMC Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ARGX's ROE is +0.24%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ARGX is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
ARGX vs APGE Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas APGE's P/E ratio is -31.19. In terms of profitability, ARGX's ROE is +0.24%, compared to APGE's ROE of -0.30%. Regarding short-term risk, ARGX is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check APGE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
ARGX vs TGTX Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, TGTX has a market cap of 8.3B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while TGTX trades at $54.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas TGTX's P/E ratio is 19.67. In terms of profitability, ARGX's ROE is +0.24%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, ARGX is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check TGTX's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
ARGX vs PRAX Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, PRAX has a market cap of 8.2B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while PRAX trades at $295.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas PRAX's P/E ratio is -22.85. In terms of profitability, ARGX's ROE is +0.24%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, ARGX is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check PRAX's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
ARGX vs CERE Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas CERE's P/E ratio is -16.47. In terms of profitability, ARGX's ROE is +0.24%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ARGX is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check CERE's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
ARGX vs CYTK Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, CYTK has a market cap of 8.2B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while CYTK trades at $65.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas CYTK's P/E ratio is -9.09. In terms of profitability, ARGX's ROE is +0.24%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, ARGX is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check CYTK's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
ARGX vs PCVX Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, PCVX has a market cap of 8.2B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while PCVX trades at $56.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas PCVX's P/E ratio is -7.40. In terms of profitability, ARGX's ROE is +0.24%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, ARGX is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check PCVX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
ARGX vs SYRE Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, SYRE has a market cap of 8.1B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while SYRE trades at $93.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas SYRE's P/E ratio is -47.79. In terms of profitability, ARGX's ROE is +0.24%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, ARGX is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check SYRE's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
ARGX vs CAI Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, CAI has a market cap of 8B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while CAI trades at $28.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas CAI's P/E ratio is 79.52. In terms of profitability, ARGX's ROE is +0.24%, compared to CAI's ROE of +0.19%. Regarding short-term risk, ARGX is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check CAI's competition here
Metsera, Inc. (NASDAQ: MTSR)
ARGX vs MTSR Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ARGX's ROE is +0.24%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, ARGX is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check MTSR's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
ARGX vs IONS Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, IONS has a market cap of 7.2B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while IONS trades at $43.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas IONS's P/E ratio is -13.31. In terms of profitability, ARGX's ROE is +0.24%, compared to IONS's ROE of -1.11%. Regarding short-term risk, ARGX is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check IONS's competition here
Immunovant, Inc. (NASDAQ: IMVT)
ARGX vs IMVT Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, IMVT has a market cap of 6.9B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while IMVT trades at $33.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas IMVT's P/E ratio is -11.92. In terms of profitability, ARGX's ROE is +0.24%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, ARGX is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check IMVT's competition here
Merus N.V. (NASDAQ: MRUS)
ARGX vs MRUS Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ARGX's ROE is +0.24%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, ARGX is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check MRUS's competition here
Abivax S.A. (NASDAQ: ABVX)
ARGX vs ABVX Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, ABVX has a market cap of 6.8B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while ABVX trades at $92.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas ABVX's P/E ratio is -15.22. In terms of profitability, ARGX's ROE is +0.24%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, ARGX is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ABVX's competition here
Arcellx, Inc. (NASDAQ: ACLX)
ARGX vs ACLX Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ARGX's ROE is +0.24%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ARGX is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
ARGX vs RETA Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas RETA's P/E ratio is -66.29. In terms of profitability, ARGX's ROE is +0.24%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ARGX is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check RETA's competition here
Belite Bio, Inc (NASDAQ: BLTE)
ARGX vs BLTE Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while BLTE trades at $159.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas BLTE's P/E ratio is -85.33. In terms of profitability, ARGX's ROE is +0.24%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, ARGX is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check BLTE's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
ARGX vs RYTM Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, RYTM has a market cap of 6.4B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while RYTM trades at $92.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas RYTM's P/E ratio is -29.85. In terms of profitability, ARGX's ROE is +0.24%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, ARGX is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check RYTM's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
ARGX vs IOVA Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, IOVA has a market cap of 6.3B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while IOVA trades at $14.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas IOVA's P/E ratio is -19.47. In terms of profitability, ARGX's ROE is +0.24%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, ARGX is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check IOVA's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
ARGX vs CNTA Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ARGX's ROE is +0.24%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ARGX is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check CNTA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
ARGX vs LGND Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, LGND has a market cap of 6.1B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while LGND trades at $302.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas LGND's P/E ratio is 33.26. In terms of profitability, ARGX's ROE is +0.24%, compared to LGND's ROE of +0.20%. Regarding short-term risk, ARGX is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check LGND's competition here
CG Oncology Inc. (NASDAQ: CGON)
ARGX vs CGON Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, CGON has a market cap of 5.9B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while CGON trades at $67.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas CGON's P/E ratio is -25.05. In terms of profitability, ARGX's ROE is +0.24%, compared to CGON's ROE of -0.25%. Regarding short-term risk, ARGX is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check CGON's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
ARGX vs KOD Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, KOD has a market cap of 5.9B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while KOD trades at $94.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas KOD's P/E ratio is -22.65. In terms of profitability, ARGX's ROE is +0.24%, compared to KOD's ROE of -2.73%. Regarding short-term risk, ARGX is less volatile compared to KOD. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check KOD's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
ARGX vs CDTX Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ARGX's ROE is +0.24%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, ARGX is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check CDTX's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
ARGX vs SRRK Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, SRRK has a market cap of 5.6B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while SRRK trades at $46.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas SRRK's P/E ratio is -13.57. In terms of profitability, ARGX's ROE is +0.24%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, ARGX is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check SRRK's competition here
Abcam plc (NASDAQ: ABCM)
ARGX vs ABCM Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ARGX's ROE is +0.24%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ARGX is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
ARGX vs ISEE Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ARGX's ROE is +0.24%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ARGX is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check ISEE's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
ARGX vs CRSP Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, CRSP has a market cap of 5.3B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while CRSP trades at $55.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas CRSP's P/E ratio is -11.64. In terms of profitability, ARGX's ROE is +0.24%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, ARGX is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check CRSP's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
ARGX vs COGT Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, COGT has a market cap of 5.3B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while COGT trades at $31.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas COGT's P/E ratio is -14.70. In terms of profitability, ARGX's ROE is +0.24%, compared to COGT's ROE of -0.73%. Regarding short-term risk, ARGX is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check COGT's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
ARGX vs PTCT Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, PTCT has a market cap of 5.3B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while PTCT trades at $63.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas PTCT's P/E ratio is -27.24. In terms of profitability, ARGX's ROE is +0.24%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, ARGX is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check PTCT's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
ARGX vs TVTX Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, TVTX has a market cap of 5.3B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while TVTX trades at $56.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas TVTX's P/E ratio is -126.51. In terms of profitability, ARGX's ROE is +0.24%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, ARGX is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check TVTX's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
ARGX vs APLS Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas APLS's P/E ratio is 38.35. In terms of profitability, ARGX's ROE is +0.24%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ARGX is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check APLS's competition here
Erasca, Inc. (NASDAQ: ERAS)
ARGX vs ERAS Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, ERAS has a market cap of 5.1B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while ERAS trades at $14.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas ERAS's P/E ratio is -15.85. In terms of profitability, ARGX's ROE is +0.24%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, ARGX is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ERAS's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
ARGX vs ORKA Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, ORKA has a market cap of 5.1B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while ORKA trades at $84.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas ORKA's P/E ratio is -43.57. In terms of profitability, ARGX's ROE is +0.24%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, ARGX is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ORKA's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
ARGX vs MIRM Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, MIRM has a market cap of 5.1B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while MIRM trades at $82.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas MIRM's P/E ratio is -5.70. In terms of profitability, ARGX's ROE is +0.24%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, ARGX is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check MIRM's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
ARGX vs DFTX Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, DFTX has a market cap of 5B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while DFTX trades at $37.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas DFTX's P/E ratio is N/A. In terms of profitability, ARGX's ROE is +0.24%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, ARGX is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check DFTX's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
ARGX vs DNTH Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, DNTH has a market cap of 4.9B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while DNTH trades at $88.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas DNTH's P/E ratio is -21.26. In terms of profitability, ARGX's ROE is +0.24%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, ARGX is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check DNTH's competition here
Veradermics, Incorporated (NYSE: MANE)
ARGX vs MANE Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, MANE has a market cap of 4.9B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while MANE trades at $116.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas MANE's P/E ratio is -37.17. In terms of profitability, ARGX's ROE is +0.24%, compared to MANE's ROE of -0.38%. Regarding short-term risk, ARGX is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check MANE's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
ARGX vs TERN Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas TERN's P/E ratio is -51.41. In terms of profitability, ARGX's ROE is +0.24%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ARGX is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check TERN's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
ARGX vs FOLD Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ARGX's ROE is +0.24%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ARGX is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check FOLD's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
ARGX vs ADPT Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, ADPT has a market cap of 4.5B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while ADPT trades at $28.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas ADPT's P/E ratio is -69.15. In terms of profitability, ARGX's ROE is +0.24%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, ARGX is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ADPT's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
ARGX vs AKRO Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ARGX's ROE is +0.24%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, ARGX is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
ARGX vs ALPN Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ARGX's ROE is +0.24%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ARGX is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check ALPN's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
ARGX vs EWTX Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, EWTX has a market cap of 4.5B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while EWTX trades at $41.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas EWTX's P/E ratio is -22.38. In terms of profitability, ARGX's ROE is +0.24%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, ARGX is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check EWTX's competition here
Opthea Limited (NASDAQ: OPT)
ARGX vs OPT Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas OPT's P/E ratio is -1.52. In terms of profitability, ARGX's ROE is +0.24%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ARGX is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
ARGX vs PRTC Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas PRTC's P/E ratio is -3.78. In terms of profitability, ARGX's ROE is +0.24%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, ARGX is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check PRTC's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
ARGX vs ABCL Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, ABCL has a market cap of 4.2B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while ABCL trades at $13.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas ABCL's P/E ratio is -25.44. In terms of profitability, ARGX's ROE is +0.24%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, ARGX is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ABCL's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
ARGX vs RLAY Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, RLAY has a market cap of 4.2B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while RLAY trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas RLAY's P/E ratio is -12.08. In terms of profitability, ARGX's ROE is +0.24%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, ARGX is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check RLAY's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
ARGX vs MRTX Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ARGX's ROE is +0.24%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ARGX is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check MRTX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
ARGX vs CPRX Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas CPRX's P/E ratio is 17.49. In terms of profitability, ARGX's ROE is +0.24%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ARGX is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check CPRX's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
ARGX vs TNGX Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, TNGX has a market cap of 3.8B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while TNGX trades at $23.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas TNGX's P/E ratio is -28.00. In terms of profitability, ARGX's ROE is +0.24%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, ARGX is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check TNGX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
ARGX vs RYZB Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ARGX's ROE is +0.24%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ARGX is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
ARGX vs CBAY Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ARGX's ROE is +0.24%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ARGX is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check CBAY's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
ARGX vs XENE Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, XENE has a market cap of 3.7B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while XENE trades at $38.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas XENE's P/E ratio is -8.09. In terms of profitability, ARGX's ROE is +0.24%, compared to XENE's ROE of -0.44%. Regarding short-term risk, ARGX is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check XENE's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
ARGX vs TLX Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, TLX has a market cap of 3.6B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while TLX trades at $10.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas TLX's P/E ratio is 110.13. In terms of profitability, ARGX's ROE is +0.24%, compared to TLX's ROE of +0.07%. Regarding short-term risk, ARGX is less volatile compared to TLX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check TLX's competition here
IDEAYA Biosciences, Inc. (NASDAQ: IDYA)
ARGX vs IDYA Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, IDYA has a market cap of 3.6B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while IDYA trades at $37.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas IDYA's P/E ratio is -19.26. In terms of profitability, ARGX's ROE is +0.24%, compared to IDYA's ROE of -0.16%. Regarding short-term risk, ARGX is less volatile compared to IDYA. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check IDYA's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
ARGX vs SWTX Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas SWTX's P/E ratio is -13.78. In terms of profitability, ARGX's ROE is +0.24%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, ARGX is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check SWTX's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
ARGX vs PBLS Comparison October 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 57.2B. In comparison, PBLS has a market cap of 3.5B. Regarding current trading prices, ARGX is priced at $919.21 on the NASDAQ, while PBLS trades at $30.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 33.14, whereas PBLS's P/E ratio is -16.11. In terms of profitability, ARGX's ROE is +0.24%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, ARGX is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check PBLS's competition here